Osphena Savings Card: The 2026 Prices, Fine Print, and Which One Is Yours

The HRT Index Editorial TeamIndependent women's health research

Published:August 28, 2026Last reviewed:August 28, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 28, 2026 · Last verified: August 28, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Start with the route that fits

Compare payer type, quantity, route, and current processing information before you choose a card or cash pathway.

Use the Osphena Price Door Finder

The manufacturer and pharmacy links on this page are not affiliate links. We earn nothing from Duchesnay USA, GoodRx, PhilRx, or any pharmacy named here. Full affiliate disclosure.

There is no single Osphena savings card price. Eligible commercially insured patients may pay as little as $45 for 30 tablets at retail, or $35 for 30 and $90 for 90 through Osphena At Home. The mail program lists $190 for 90 when Osphena is uninsured or not covered. Medicare follows separate cash rules; Medicaid and TRICARE are excluded.

That's the answer. Here's the part nobody tells you: the number you pay depends on your payer type, your quantity, and which door the prescription goes through — not one universal coupon. Duchesnay currently publishes several price points across its mail, retail, and cash pathways. One quantity-and-route question can change the advertised annual math by $60, $180, or $260.

Is this page for you?

Best for you if:

You already have an Osphena prescription or expect one soon.
You have commercial insurance, no insurance, Medicare Part D, or a plan that denied coverage.
You were quoted a price that made you put the phone down.
You want to know whether 30 or 90 tablets changes the published price.

Not for you if:

You are looking for a diagnosis or a recommendation that Osphena is right for you. A clinician has to make that decision.
You have unexplained bleeding after menopause or symptoms that may need urgent evaluation. Start with the safety section, not a coupon.
You are enrolled in Medicaid, TRICARE, or another government-funded plan and are looking for the commercial card. The published terms exclude it; use the government-plan section.
You do not have a prescription yet. A savings card cannot create one.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Before you download an Osphena savings card

The live Osphena savings page and the downloadable January 2026 PDF agree on the advertised prices and the retail Apollo card, but they display different GoodRx processing information. That is enough to derail a claim if a saved card is stale. Open the live manufacturer page on the day you fill and ask the pharmacist to use the current information shown there.

This is the most important original verification on this page.

On August 28, 2026, we compared Duchesnay's live savings page with the PDF served by its download button. The PDF is marked January 2026. The advertised dollar amounts match. The Apollo retail-card block matches. The GoodRx BIN, PCN, group, and ID block does not.

We are deliberately not reproducing those codes here. A static article is exactly where an old code becomes a new rejection.

What to do: open the live savings page at the pharmacy counter. If the pharmacist is working from a saved PDF, an older card, or information already stored in your profile, compare it with the live page before the claim is run. If the claim still fails, ask for the exact rejection message.

What are the four Osphena savings routes?

The four practical routes are commercial insurance through Osphena At Home, commercial insurance through the retail card, cash through Osphena At Home, and the manufacturer-listed GoodRx cash offer. The lowest advertised annualized amount is $360 through the 90-tablet commercial mail route; the 30-tablet retail card annualizes to $540.

Every manufacturer figure below is an advertised “as little as” amount, not a guaranteed price. The pharmacy or mail program determines your actual amount when it processes the claim.

Your situation	Route	Quantity	Advertised amount	Normalized per 30 days	Normalized per 360 days	Insurance billed?
Commercial insurance	Osphena At Home	90 tablets	$90	$30.00	$360	Yes
Commercial insurance	Osphena At Home	30 tablets	$35	$35.00	$420	Yes
Commercial insurance	Retail CoPay Savings Card	30 tablets	$45	$45.00	$540	Yes
No insurance or Osphena not covered	Osphena At Home cash route	90 tablets	$190	$63.33	$760	No — cash
No insurance or Osphena not covered	Manufacturer-listed GoodRx route	90 tablets	$205	$68.33	$820	No — cash
No insurance or Osphena not covered	Manufacturer-listed GoodRx route	30 tablets	$85	$85.00	$1,020	No — cash
No savings route	Ordinary retail cash benchmark	30 tablets	About $258	About $258	About $3,096	No — cash
Medicare Part D, paying outside the benefit	Separate cash pathway	90 tablets	$190 reported; confirm	$63.33	$760	No — does not count toward Part D TrOOP
Medicaid, TRICARE, or another government plan	Commercial savings offers	—	Not eligible under published terms	—	—	—

How to read this table: “commercial” means employer-sponsored or privately purchased coverage, not Medicare, Medicaid, TRICARE, or another government-funded plan. “Normalized” is comparison math: twelve 30-tablet fills or four 90-tablet fills at the same advertised amount. It is not a promise that the offer or your eligibility stays unchanged for 360 days. The ordinary retail benchmark is a current Drugs.com cash-price snapshot, not a manufacturer amount. (Manufacturer savings page; January 2026 terms; Drugs.com price guide)

Four things the route table exposes

1. The verified commercial route difference is $180 a year. At the advertised minimums, twelve $45 retail fills total $540. Four $90 mail fills total $360.

2. Even inside Osphena At Home, quantity changes the math by $60 a year. Twelve $35 fills total $420; four $90 fills total $360.

3. A cash payer comparing 30-tablet GoodRx fills with 90-tablet Osphena At Home fills sees a $260 annual difference. Twelve $85 fills total $1,020; four $190 fills total $760.

4. Duchesnay's own mail cash route is $15 lower per 90 tablets than the GoodRx amount displayed beside it. That is $60 over four 90-tablet fills.

Use the Osphena Price Door Finder

No account or health history is needed. Start with payer type, quantity, and route.

The right online HRT provider isn't the same for every woman

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

What did The HRT Index actually verify?

We verified the current manufacturer page, its January 2026 PDF, the patient and prescriber savings pages, the FDA-approved label, the FDA generic approval record and Orange Book status, the 2026 Medicare Part D threshold, and current public provider terms. We did not enroll, fill a prescription, call the phone lines, or run a pharmacy claim.

Checked directly on August 28, 2026:

Duchesnay's live savings page
The January 2026 manufacturer savings PDF
Duchesnay's patient FAQ and prescriber savings page
The current FDA-approved Osphena label on DailyMed, revised February 2025
FDA's approval letter for ANDA 215574 and current Orange Book resources
CMS's 2026 Part D redesign instructions
Current public price pages used only for context, not as manufacturer guarantees
Current public terms for the prescription-access options named later on this page

What we did not do, and will not pretend we did:

We did not enroll in Osphena At Home.
We did not fill Osphena or submit a test claim.
We did not independently call and authenticate each phone line; the numbers below are the numbers currently published by Duchesnay.
We cannot determine your eligibility or your final copay from a webpage.
We did not confirm inventory at every pharmacy that may list ospemifene.

Who created this: The HRT Index Editorial Team. This page follows The HRT Index Verification Standard — the documented process of reading every published price, separating FDA-approved from compounded products, verifying availability and insurance, and re-checking on a fixed schedule. It evaluates exactly five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, and access. It is not a numeric score, and no product or provider has been given one here.

Found something that changed? Send the source and fill date through our corrections policy.

How much does the Osphena savings card actually save you?

At current published amounts, the best commercial mail route annualizes to $360, the manufacturer cash routes annualize to $760–$1,020, and an ordinary $258-per-30-tablet cash benchmark annualizes to about $3,096. The full route spread is about $2,736, but those endpoints apply to different payer situations and are not interchangeable promises.

Here is the thing about “as little as.” It is doing real work.

The manufacturer amounts are floors for eligible transactions, not universal checkout prices. Commercial offers depend on the claim, plan contribution, quantity, route, and program terms. The cash amounts still depend on the program accepting the prescription and the transaction being processed through the correct pathway.

Average. Not yours.

So treat every published number like a quote target, not a receipt.

Does shopping around still matter?

The manufacturer-linked GoodRx offer is unusually flat: Duchesnay publishes $205 for 90 tablets, while GoodRx currently displays $205.20 against an average retail price above $900. That partner rate is not the same thing as the ordinary cash market. (GoodRx Osphena price)

Shopping still matters for three reasons:

A pharmacy may or may not accept the manufacturer card.
A pharmacy may already have an older processing record stored.
Ordinary cash quotes can vary even when the manufacturer-linked GoodRx rate does not.

What this means for you: route, quantity, coverage, and processing come first. Pharmacy shopping comes after those four facts are straight.

Which Osphena savings option applies to me?

Commercially insured patients should compare the mail program with the retail card. Uninsured or noncovered patients should compare the $190 mail cash route with the $85/$205 GoodRx route. Medicare Part D users must compare plan coverage with a separate cash purchase outside Part D; Medicaid and TRICARE users are excluded from the published manufacturer offers.

The Osphena Price Door Finder

Choose the row that matches your payer and prescription. This is a routing tool, not an eligibility determination or price guarantee.

Your situation	Published route to check first	Published amount	What to do next
Commercial insurance, 90 tablets, delivery is acceptable	Osphena At Home	$90 for 90	Ask whether the prescription can be sent to Osphena At Home; have the program run the claim
Commercial insurance, 30 tablets, delivery is acceptable	Osphena At Home	$35 for 30	Compare with the 90-tablet option before the prescription is finalized
Commercial insurance, local pharmacy preferred	Retail CoPay Savings Card	$45 for 30	Open the live card and ask the pharmacy to run the current information
No insurance or plan does not cover Osphena, delivery is acceptable	Osphena At Home cash	$190 for 90	Confirm the cash quote and that insurance will not be billed
No insurance or noncovered, local pharmacy preferred	Manufacturer-listed GoodRx	$85 for 30 or $205 for 90	Compare the live GoodRx amount with the $190 mail quote
Medicare Part D	Plan claim first, then compare with cash outside Part D	Plan-specific or $190 for 90 cash reported	Ask whether Osphena is covered, whether prior authorization is required, and what your Part D price is before choosing cash
Medicaid, TRICARE, or another government plan	Manufacturer commercial offers do not apply	No published eligible amount	Call the plan and Osphena program; do not assume the Medicare cash lane extends to you
No prescription	Clinical visit first	Visit cost varies	Ask the five prescription and quantity questions below before paying for medication

Printable pharmacy quote sheet

Use one row per quote. Do not write a diagnosis, date of birth, member ID, or other sensitive information on a sheet you plan to carry around.

Route or pharmacy	Quantity	Insurance billed?	Quoted amount	Card/page date checked	Name or reference number	Notes
____________________	______	Yes / No	$________	__________	____________________	____________________
____________________	______	Yes / No	$________	__________	____________________	____________________
____________________	______	Yes / No	$________	__________	____________________	____________________

Open the current official Osphena savings page

Official manufacturer site. Not an affiliate link.

Is Osphena At Home cheaper than the retail card?

Yes, at the advertised minimums. Commercially insured patients are shown $35 for 30 or $90 for 90 through Osphena At Home, compared with $45 for 30 through the retail card. The 90-tablet mail route annualizes to $360; the 30-tablet retail route annualizes to $540.

Osphena At Home currently includes free delivery, on-staff pharmacists, insurance benefit verification, refill reminders, prescription transfers, and refill outreach to the prescriber. Duchesnay publishes (844) 716-HOME (4663) for enrollment, Monday–Friday 9 a.m.–8 p.m. Eastern and Sunday 9 a.m.–1 p.m. Eastern. (Osphena FAQ)

Automatic refills have a real tradeoff: PhilRx keeps the payment card on file. The FAQ says you can decline automatic refills and call for each shipment instead.

A small inconsistency that is not really small

Duchesnay's current FAQ says Osphena At Home is offered through PhilRx, and the January 2026 PDF says the program is available only through PhilRx. One adjacent enrollment instruction on the same FAQ still says a Transition Pharmacy representative will call.

That does not prove anything improper. It proves the public instructions have not been fully harmonized.

If a caller or message uses a vendor name you did not expect, do not rely on the name alone. Confirm the official program, prescription, and phone number through Osphena.com before giving payment or insurance information.

Call Osphena At Home and ask for the 30- and 90-tablet quotes

Published number: (844) 716-HOME. Ask for both quantities before the prescription is finalized.

What does Osphena cost without insurance?

Duchesnay currently publishes $190 for 90 tablets through Osphena At Home when the patient has no insurance or Osphena is not covered. That is about $63.33 per 30 days and $2.11 per tablet. The manufacturer-listed GoodRx route is $205 for 90 or $85 for 30.

The cost-saving question is not simply “Can you write 90?” It is:

“If a 90-tablet prescription is clinically appropriate for me, can it be sent through the route that qualifies for the 90-tablet price?”

That wording matters. Quantity is a clinical and prescribing decision, not a coupon trick.

At the published amounts:

Four $190 mail fills total $760 over 360 days.
Twelve $85 GoodRx fills total $1,020.
The difference is $260.

But there is a second cost: unused medication. A clinician may reasonably want an earlier reassessment, and some patients stop because of side effects or lack of benefit. A 30-tablet fill can cost more per tablet and still waste less if treatment stops early. The right answer is the quantity your clinician considers appropriate after you both see the cost difference.

Use the quote sheet before you choose cash

Can I use the Osphena savings card with Medicare?

No. Medicare beneficiaries cannot use the commercial Osphena copay card. Duchesnay's current terms describe a separate Part D cash transaction outside the benefit, and the current program listing reports $190 for 90 tablets. That cash purchase cannot be submitted to Part D and does not count toward the Part D out-of-pocket threshold.

Three things are true at once.

One: the commercial card is excluded. The current manufacturer terms exclude Medicare, Medicaid, TRICARE, and other federal or state health plans from the commercial savings offers.

Two: Medicare Part D has a separately described cash lane. The January 2026 terms explain that a Part D patient may elect to pay cash outside the benefit. Current program information reported by Drugs.com lists $190 for 90 tablets with home delivery. Confirm the exact quote with the program before the prescription moves. (Manufacturer terms; Drugs.com program listing)

Three: the invisible cost is TrOOP. The manufacturer terms state that the cash purchase cannot be submitted to Part D and does not count toward the Part D total out-of-pocket threshold.

The 2026 Part D threshold is $2,100. After a beneficiary reaches that amount through covered Part D spending, covered Part D drugs enter catastrophic coverage with no further out-of-pocket cost for the rest of the year. (CMS 2026 instructions; Medicare Part D costs)

Here is the calculation nobody should make you do at the counter:

Four $190 fills total $760. That is 36.2% of the $2,100 threshold — and a cash transaction outside Part D moves you zero dollars toward it.

So compare two annual outcomes, not two single-fill prices:

If other covered prescriptions are likely to push you to $2,100: ask the plan for its Osphena price, prior-authorization rules, and coverage-determination process before choosing cash.
If you are unlikely to reach $2,100: compare the plan price with the $190 cash quote. The cash route may still be lower, but it is not automatically lower.

The current January 2026 manufacturer sheet also describes Osphena as a preferred brand in certain AARP/UnitedHealthcare, Wellcare, and Humana Part D arrangements. Treat that as a manufacturer statement, not a coverage guarantee. Formularies differ by exact plan and can change during annual updates. Call the number on your Part D card and ask about Osphena 60 mg, quantity 90, prior authorization, step therapy, and tier.

If the drug is not covered, ask for a coverage determination or formulary exception and what supporting statement the prescriber must submit. Do not abandon the plan route until you know the answer.

No provider or product CTA belongs in this section. The next correct action is a plan call.

What if I have Medicaid, TRICARE, or another government plan?

The published manufacturer commercial offers exclude Medicaid, TRICARE, and other federal or state health plans. The manufacturer terms contain a specific cash explanation for Medicare Part D, but they do not publish the same named exception for every government program. Do not assume the $190 Medicare lane applies to you.

Call three places in this order:

Your plan's pharmacy-benefit number.
Osphena At Home at (844) 716-HOME (4663).
Your prescriber's office if the plan requires a prior authorization, preferred alternative, or medical-necessity statement.

Ask the program to state the eligibility rule in plain language before transferring the prescription. A general cash discount may be a separate transaction, but the manufacturer offer must be used under its own terms.

Why does the age of the trial population matter to the savings card?

The four pivotal Osphena trials had mean ages of 59, 59, 60, and 62, while Medicare eligibility commonly begins at 65. Genitourinary syndrome of menopause can persist and typically worsens over time without effective treatment. That means the need for treatment may continue after commercial-card eligibility ends.

This is not a claim that every woman needs Osphena indefinitely. The label says treatment should be used for the shortest duration consistent with the individual's goals and risks and reevaluated periodically.

It is a structural collision worth seeing:

The core study populations were close to Medicare age.
The condition can continue rather than burn out like a short-lived symptom.
The commercial card disappears when a woman moves into a government-funded plan.

The label also reports that more than 19% of Osphena-treated women across ten trials were age 65 or older and that no clinically meaningful safety or effectiveness differences were observed between older and younger groups in those trials. The savings exclusion is a program rule, not evidence that the medication stops being relevant at 65. (FDA-approved label; The Menopause Society's GSM MenoNote)

We cannot fix that structure. But you should know the price jump is not a personal failure to find the right coupon.

Is there a patient assistance program for Osphena?

No. Duchesnay's current FAQ states that it does not offer a patient assistance program. The available manufacturer-supported paths are the commercial mail and retail offers plus the published cash route; the company does not list a free-drug or income-based patient-assistance pathway.

Here is the honest gut-punch on this page.

If you are uninsured, have a low income, and were expecting an application that could reduce the price to zero, that program does not exist here. No coupon directory can create it.

The manufacturer does not publish why it chose this structure, so we will not invent a charity-to-cash tradeoff.

What we can prove is the pivot:

Current ordinary cash price: about $258 for 30 tablets.
Current GoodRx average retail benchmark: about $902 for 90 tablets.
Current Osphena At Home cash route: $190 for 90 tablets.

Against the $902 benchmark, $190 is about 79% lower. That is a meaningful cash price. It is still $190 every 90 days, and meaningful does not mean affordable for everyone.

If $190 per fill is outside your budget, the honest next step is not another hidden coupon. It is a conversation about whether a different FDA-approved route fits your symptoms, history, and preferences. Compare the treatment formats below.

No CTA here. The damaging admission needs room to be believed.

Why did my Osphena savings card not work?

A rejection can come from payer ineligibility, stale processing information, the wrong quantity, refill timing, a pharmacy that does not accept the offer, or an insurer requirement such as prior authorization. Ask the pharmacist for the exact rejection message before leaving, then compare the claim with the live manufacturer page while it is still open.

The most useful question at the counter is:

“What did the rejection message actually say?”

“The card didn't work” hides several different failures. Each has a different fix.

Work through this in order

Confirm there is a valid prescription. The card and At Home program both require one.
Confirm the payer type. Medicare, Medicaid, TRICARE, and other government plans cannot use the commercial card.
Compare the current processing information. Open the live savings page rather than relying on a saved PDF or pharmacy profile.
Check the quantity. The public offers are built around 30 and 90 tablets.
Ask whether the rejection is “refill too soon.” The card itself does not impose a waiting period, but the insurer can.
Ask whether that location accepts the card. Duchesnay says most U.S. and Puerto Rico retail pharmacies accept it, not all.
Ask about the rebate route before paying. The FAQ says a patient may pay, then request a rebate check if a pharmacy declines the card. Get the submission instructions first so you know what receipts and documents are required.
Confirm the prescription is at the right pharmacy for the desired route. The mail price requires the mail pathway.
Separate processor rejection from insurer rejection. Prior authorization, step therapy, and formulary exclusion are plan problems, not card-code problems.
Call while the claim is still visible. A live rejection is easier to explain than a memory of one.

Was it the card or the insurance plan?

What the pharmacy says	What it may mean	Next action
“The coupon was rejected”	Processing data, card eligibility, quantity, or processor rule	Compare with live card; call retail program
“The drug is not covered”	Formulary exclusion	Ask for plan coverage determination or exception process
“Prior authorization required”	Plan wants clinical documentation	Prescriber's office submits the request
“You must try another drug first”	Step therapy	Prescriber addresses the preferred alternatives and medical rationale
“Refill too soon”	Plan timing rule	Ask when it can be filled or whether an override applies
“We don't accept the card”	Store or processor policy	Ask about rebate instructions or another participating pharmacy
“The quantity is not covered”	Plan or offer quantity mismatch	Prescriber and plan decide whether the quantity can change

Screenshot these five things

Before leaving the manufacturer page, capture:

The date.
The full page URL.
The current processing block.
The support phone number.
The amount and quantity attached to the offer.

A screenshot is a backup, not a permanent source of truth. Reopen the live page before the next fill.

Who to call

Situation	Published number
Osphena At Home / mail program	(844) 716-HOME (4663)
Retail savings-card questions	(347) 657-9766
Osphena customer service or product questions	1-855-677-4362

Numbers rechecked against current manufacturer pages on August 28, 2026. We did not independently place test calls.

Open the live Osphena savings page before the claim is run

Does the Osphena card work at CVS, Walgreens, Walmart, and mail-order pharmacies?

Duchesnay says the card is accepted at most retail pharmacies in the United States and Puerto Rico and may be used for mail-order purchases with a valid prescription. It does not guarantee acceptance at every CVS, Walgreens, Walmart, Costco, independent pharmacy, or individual location.

A chain logo is not an eligibility decision.

Call the exact location and ask:

Do you stock Osphena 60 mg or can you order it?
Can you process the current Osphena manufacturer copay card?
What is the quote for the quantity on my prescription?
If the card is declined, can you give me the rejection message and receipt needed for the manufacturer's rebate process?

Two minutes on the phone beats a trip. If the answer is no, the mail route or another location may still work.

What if my insurance will not cover Osphena?

A commercial-plan denial does not automatically mean full retail. Osphena At Home says it can verify benefits and work with the prescriber's office on coverage restrictions, while its cash route lists $190 for 90 tablets when Osphena is not covered. First identify whether the problem is formulary status, prior authorization, step therapy, quantity, or processing.

A denial is not one thing.

Denial type	What it means	Best next move
Not on formulary	The plan does not list Osphena for routine coverage	Ask how to request a coverage determination or exception
Prior authorization	Clinical information is required before coverage	Prescriber submits the plan's form or electronic request
Step therapy	Plan wants another covered option tried first	Prescriber explains prior treatment or why the required option is inappropriate
Quantity limit	Plan covers only a defined quantity per fill	Ask whether the plan or prescription quantity can be adjusted
Plan exclusion	Benefit does not cover the drug/category	Compare the $190 mail cash route with retail cash
Processor rejection	The savings transaction failed, not the insurance decision	Return to the card-troubleshooting steps

Osphena At Home says PhilRx will work with the prescriber's office when the insurer places coverage restrictions. That is a coordination service, not a promise that the plan will approve the drug.

The practical fork:

Need the prescription now and can pay cash: compare the current $190 mail quote with the local cash quote.
Can wait for the plan process: pursue the coverage determination first, because an approved plan price may be lower and may count toward Part D or commercial-plan cost sharing.

How long does Osphena take to work — and should I ask for 90 tablets?

The pivotal efficacy trials measured outcomes at 12 weeks, but that does not establish a mandatory 12-week trial for every patient or make 90 tablets automatically right. A 90-tablet fill has the lowest published unit cost on the mail routes; a 30-tablet fill can reduce unused-medication cost when a clinician wants earlier reassessment.

Twelve weeks is 84 days. A 90-tablet prescription maps closely to the time point used in the pivotal trials, and the published 90-tablet routes have lower normalized costs than the 30-tablet routes.

That is a useful cost connection. It is not a dosing rule.

The label also says treatment should use the shortest duration consistent with the individual's goals and risks and be reevaluated periodically. Ask the clinician three questions:

When should we reassess whether it is helping?
What side effect or symptom should make me call sooner?
Given that plan, is 30 or 90 tablets the appropriate first quantity?

The blood concentration reaches steady state in about nine days. That pharmacokinetic fact does not tell you when your symptoms will improve or when to decide that treatment has failed. (FDA-approved label)

Take it with food — that is a label instruction

The approved directions are one 60 mg tablet once daily with food. Food increases ospemifene exposure by roughly two to three times in the pharmacokinetic studies, which is why the instruction belongs in the prescription directions.

Do not turn that into a verdict about one missed meal or change the dose yourself. Take it as directed and ask the pharmacist what to do if your routine is inconsistent.

Missed dose? Duchesnay's FAQ says to take the next regularly scheduled tablet and not take two in the same day.

Compare the 30- and 90-tablet route math

Is there a generic for Osphena?

FDA approved Hetero Labs' ospemifene 60 mg ANDA in February 2024 and found it bioequivalent and therapeutically equivalent to Osphena. FDA's Orange Book later moved that product to discontinued status. An approved application exists, but we did not identify a currently marketed, routinely fillable generic on August 28, 2026.

This is more complicated than “there is no generic.”

What the FDA record shows:

Hetero received tentative approval in June 2023.
FDA granted full approval to ANDA 215574 on February 13, 2024.
The approval letter states that the product is bioequivalent and therapeutically equivalent to Osphena 60 mg.
The application was eligible for 180 days of generic exclusivity, subject to the statutory conditions and possible forfeiture.
A subsequent Orange Book cumulative supplement moved the product to discontinued status.

Translation: approved is not the same as marketed, stocked, or fillable.

That distinction matters for two reasons.

First: a pharmacy system or telehealth page may use the generic name “ospemifene” even when the dispensed product would need to be brand Osphena. Ask what product and National Drug Code the pharmacy can actually obtain.

Second: an unfamiliar website advertising “generic Osphena” is not proof that the FDA-approved Hetero product is commercially available. Use a licensed U.S. pharmacy you can identify and contact.

Ask the pharmacy to check current inventory; do not assume a database headline is a shelf-level answer. (FDA approval letter; FDA Orange Book)

What other FDA-approved options may cost less?

Osphena is the FDA-approved oral tablet for moderate-to-severe painful sex and vaginal dryness due to menopause, but it is not the only FDA-approved treatment route for those symptoms. Generic vaginal estradiol cream can have a much lower cash price, while products such as Intrarosa remain brand-only and may cost more than the Osphena cash program.

This is not a substitution chart. It is a question list for the clinical conversation.

FDA-approved option	Route	Current cash/coupon snapshot	Generic availability	What changes the decision
Osphena (ospemifene)	Oral tablet daily	$90/90 commercial mail; $190/90 cash mail	FDA-approved generic application exists, but no marketed product identified	Oral route, systemic exposure, label warnings, interactions, coverage
Estradiol vaginal cream 0.01%	Vaginal cream	About $35 for one 42.5 g tube on a current GoodRx snapshot	Yes	Dose and tube duration vary; local application; individual history
Estradiol vaginal tablet/insert	Vaginal tablet or insert	Product, quantity, and pharmacy vary	Generic products exist for some formulations	Local application, schedule, coverage, comfort with insertion
Estring	Vaginal ring replaced every 90 days	Brand price varies widely	No lower-cost generic identified	90-day local route, insertion/removal, coverage
Intrarosa (prasterone)	Vaginal insert nightly	About $303 for 28 inserts on a current GoodRx snapshot	No	Daily insertion, brand-only cost, individual history

Price snapshots were checked August 28, 2026 and can change by pharmacy and location. They are not equivalent quantities or treatment courses. (GoodRx estradiol price; GoodRx Intrarosa price)

Do not stack Osphena with estrogen on your own

The Osphena label says not to use it concomitantly with estrogens or other estrogen agonists/antagonists because the safety of combined use has not been studied.

So the question is not “Which cheap product can I add?” It is “Which single treatment plan fits my symptoms and history, and what should happen to anything I already use?”

Do not stop, add, or switch a prescription without the prescribing clinician.

The cost question worth taking to the visit

Ask:

“Is an FDA-approved local treatment a reasonable fit for me, and if not, what specific part of my symptoms, history, or route preference makes oral Osphena the better choice?”

There may be a good reason. Make sure it is a reason someone actually considered.

For a deeper route comparison, see our guide to vaginal estrogen options.

“Non-hormonal” describes the chemistry, not the risk

The Osphena label says it is not a hormone; it is an estrogen agonist/antagonist with tissue-selective effects. The same label carries a boxed warning for endometrial cancer and cardiovascular disorders. “Non-hormonal” describes what the tablet is, not a promise that it has no estrogen-like effects or serious risks.

Osphena acts as an estrogen agonist in some tissues and an antagonist in others. In the vaginal tissue, that action is part of how it treats dryness and painful sex. In the endometrium, the label says it has estrogen-agonist effects.

Now the 2026 context:

FDA's current page lists updated prescribing information for six menopausal hormone-therapy products, including Estring, Prometrium, Divigel, Cenestin, Enjuvia, and Bijuva. Osphena is not on that list; its current label remains revised February 2025 and retains its boxed warning. (FDA updated MHT labels; Osphena label)

That does not prove one treatment is safer than another. You cannot compare drugs by counting warning boxes, and this page will not try.

It proves one narrower point: do not let the word “non-hormonal” make the risk decision for you. Read the actual label and let a clinician apply it to your history.

Is Osphena worth $360 to $820 a year?

The pivotal trials showed statistically significant average improvement over placebo for painful sex in two trials and vaginal dryness in two of three trials. The drug-placebo difference on the 0-to-3 symptom-severity scale was about 0.3–0.5 points. One vaginal-dryness comparison did not reach statistical significance.

Every savings page can show you a coupon. A decision page should also show you what the money is buying.

Symptom-severity change at 12 weeks

Trial	Most bothersome symptom	Osphena 60 mg	Placebo	Drug-placebo difference
Trial 1	Painful sex	−1.4	−0.9	0.5
Trial 2	Painful sex	−1.5	−1.2	0.3
Trial 1	Vaginal dryness	−1.3	−0.9	0.4
Trial 3	Vaginal dryness	−1.3	−0.9	0.4
Trial 2	Vaginal dryness	Not statistically significant versus placebo	—	—

Rounded from Tables 3 and 4 of the FDA-approved label. The baseline average symptom scores were approximately 2.5–2.7 on a scale from 0 (none) to 3 (severe).

Read that honestly.

The placebo groups improved substantially. The average additional benefit attributable to the drug was modest on that scale, and one dryness analysis missed statistical significance. That is not a reason to dismiss the treatment. Averages contain women who improve a great deal, women who improve a little, and women who do not improve.

It is the evidence to hold beside the price — not beneath it.

Common adverse reactions, with the placebo column

Adverse reaction	Osphena	Placebo
Hot flushes, 12-week trials	6.5%	2.6%
Hot flushes, 52-week trial	12.2%	4.2%
Vaginal discharge, 12-week trials	3.8%	0.4%
Vaginal discharge, 52-week trial	6.0%	0.6%
Muscle spasms, 52-week trial	4.5%	2.4%

The label warns that Osphena may initiate or increase hot flashes in some women. If dryness is the target symptom but hot flashes are already disrupting sleep or work, bring that tradeoff into the decision before the first fill.

How many women completed the 52-week study?

The long-term safety study randomized 426 women: 363 to ospemifene and 63 to placebo. 349 women, or 81.9%, completed the study. Adverse events were the most common reason for discontinuation; treatment-emergent adverse events led to discontinuation in 9.5% of the ospemifene group and 3.9% of the placebo group. (Peer-reviewed 12-month study)

That is not the 39% drug-discontinuation rate sometimes produced by using the wrong denominator. It is still a cost issue: if treatment stops, unused tablets are part of what you paid for.

Two interactions worth saying out loud

The label says:

Do not use Osphena with fluconazole. Fluconazole increased ospemifene exposure about 2.7-fold in the interaction study.
Avoid using Osphena with rifampin. Rifampin reduced ospemifene exposure by 58%.

Do not infer a diagnosis from vaginal discharge or self-treat an infection from this page. The practical action is simpler: when any clinician or pharmacist is considering a new prescription, say “I take Osphena” and ask them to check the interaction list.

No CTA here. This section exists to make the spending decision honest.

When online care isn't the right starting point

Osphena is contraindicated with undiagnosed abnormal genital bleeding, known or suspected estrogen-dependent cancer, current or prior DVT or pulmonary embolism, current or prior stroke or heart attack, hypersensitivity, or pregnancy. The label separately says severe hepatic impairment is not recommended and known, suspected, or prior breast cancer should not use it because it has not been adequately studied.

The distinctions matter.

Formal contraindications are not the same as every warning or “not recommended” population. Keeping those categories separate changes what a reader should do next.

Unexplained bleeding after menopause needs evaluation before a prescription. The label calls for diagnostic measures when abnormal genital bleeding is undiagnosed, persistent, or recurring.

Seek emergency care for possible stroke, heart attack, or blood-clot symptoms such as sudden changes in speech or vision, a new severe headache, chest pain, a painful or swollen leg, or shortness of breath.

If you have or have had breast cancer, the label says Osphena has not been adequately studied in that population and should not be used. If vaginal symptoms are occurring during tamoxifen or aromatase-inhibitor treatment, start with your oncology team. Our background guides on vaginal estrogen and tamoxifen and vaginal estrogen and aromatase inhibitors can help you prepare questions, but they do not replace that discussion.

If you have severe liver impairment, the label says Osphena should not be used because its pharmacokinetics have not been studied there. That is a labeled limitation, even though it is not listed in the formal contraindications section.

We are a cost and decision resource. We cannot tell you whether this prescription is right for you, and a coupon cannot answer that question either.

Do I need a prescription to use the Osphena savings card?

Yes. The retail card and Osphena At Home require a valid Osphena prescription. The savings program changes how an eligible prescription is paid for; it does not diagnose the condition, bypass a clinician, or guarantee that a clinician will prescribe the drug.

If you do not have a prescription, ask these five questions at the visit:

Is Osphena a reasonable fit for my symptoms and history?
When will we reassess benefit and side effects?
Is 30 or 90 tablets the appropriate first quantity?
Can the prescription be sent through Osphena At Home if that route fits?
Does my plan require prior authorization or step therapy?

Question 3 is where clinical judgment and cost finally meet.

The manufacturer-linked nonaffiliate route

Osphena.com links to MyMenopauseRx with a notice that its healthcare professionals are independent and exercise autonomous clinical judgment. MyMenopauseRx currently says it accepts many insurance plans, sends prescriptions to the patient's chosen pharmacy, and offers self-pay visits at $150. Its current FAQ says it does not bill Medicare, Medicaid, or HMO plans; confirm self-pay eligibility before booking if you have one of those plans. We earn nothing from that route. Availability and insurance participation depend on state and plan. (MyMenopauseRx treatment costs)

See current visit availability through MyMenopauseRx

Independent telehealth provider linked by the manufacturer. Not an affiliate link. A visit does not guarantee a prescription.

A cash-pay marketplace route — with a real insurance limitation

Sesame publishes an ospemifene/Osphena visit page and says an independent provider may send a prescription to the patient's preferred pharmacy if appropriate. That pharmacy-choice model can work with a manufacturer card because Sesame is not bundling the medication into the visit price. (Sesame ospemifene page)

The honest catch: Sesame is cash-pay. Its current terms say it does not accept Medicare, Medicaid, or any other third-party insurance, and cash payments through Sesame do not count toward prescription-drug coverage out-of-pocket totals. That makes it a poor route if you need the visit or medication billed to a plan, although the current terms do not categorically bar beneficiaries from buying a cash visit. Confirm the exact pharmacy route before booking. (Sesame terms)

Sesame's current medication page also uses “generic for Osphena” language even though FDA's approved generic product is listed as discontinued and we did not identify a marketed generic. Ask the clinician and pharmacy whether the intended prescription is brand Osphena and what product is actually available before paying.

Check current cash-pay visit options on Sesame

For readers who are intentionally choosing a cash-pay visit and want to keep a preferred pharmacy. We may earn a commission; see our disclosure. A visit does not guarantee a prescription.

Why compounded providers are not featured here

Osphena is an FDA-approved brand-name prescription drug with a specific label, trial record, and savings program. Compounded medications are not FDA-approved and must not be presented as equivalent to Osphena. Providers that primarily sell compounded therapies may be relevant to a different question; they are not the answer to an Osphena savings-card query.

In their own words

These comments show cost and discontinuation friction, not typical savings, effectiveness, or safety. They are individual WebMD reviews, and The HRT Index did not independently verify the reviewers' insurance claims or medical experiences.

“90 day supply through Humana cost $141.00.”
— WebMD reviewer, January 2024

One plan, one year, one person's transaction. It is evidence that a Part D price can differ sharply from the cash route, not a price anyone else should expect.

“I took 22 of a 30 pill prescription. I stopped when I had the first yeast infection...”
— WebMD reviewer, December 2023

That is why the quantity decision has two sides. Ninety tablets can lower the unit cost; thirty can limit unused medication when treatment stops early.

We intentionally excluded reviews that claim the drug prevents cancer or prove medical effectiveness. Anecdotes cannot establish either.

Source: WebMD Osphena patient reviews.

Osphena savings card FAQ

Does the Osphena savings card need to be activated?

No. Duchesnay's current FAQ says it does not need activation before first use.

Can I reuse the same card?

Yes. The FAQ says one card can be used for several fills, only one card may be used at a time, and a pharmacy may keep the information on file. Bring or reopen the current card anyway because processing information can change.

Do I still need a prescription?

Yes. The card is valid only with a prescription for Osphena.

Can I use the card before meeting my deductible?

Duchesnay says yes and says the out-of-pocket expense can be applied to the deductible. Your plan controls how manufacturer assistance is counted in its own deductible and out-of-pocket accounting, so confirm the plan's rule.

Can I use the card with a mail-order pharmacy?

Yes, with a valid prescription. Osphena At Home is the manufacturer-supported mail route and publishes lower minimums than the retail card.

Is shipping free through Osphena At Home?

Yes. Duchesnay says shipping is included with the prescription order.

Can I set up automatic refills?

Yes. PhilRx says automatic monthly refills are available for the length of the prescription. Automatic refill requires a payment card on file; you can decline and request each refill manually.

Is there a required wait between fills?

Not under the card itself. The FAQ says the card does not require a specific waiting period, but the insurer may restrict how soon it will approve the next fill.

What if my pharmacy refuses the card?

Duchesnay says a patient may purchase the prescription and request a rebate check. Call the number on the back of the current card for instructions before paying, so you know the documentation and deadline.

Can I combine the manufacturer card with GoodRx?

No. They are alternative payment paths. The manufacturer terms prohibit combining the offer with another coupon, discount, or similar offer.

Does the card expire?

The current public offer does not show a conventional expiration date, but the terms let Duchesnay amend, revoke, or rescind it at any time. Check the live page before each fill.

Can Medicare patients use the card?

Not the commercial card. A Part D beneficiary may compare plan coverage with the separately described cash transaction outside Part D, which does not count toward TrOOP.

Can Medicaid or TRICARE patients use it?

The published terms exclude them from the manufacturer savings offers. The Medicare Part D cash language should not be assumed to apply to every government plan.

Is there a patient assistance program?

No. Duchesnay says it does not offer one at this time.

Is a generic available?

FDA approved a generic application, but the Orange Book later listed that product as discontinued. We did not identify a current marketed generic on August 28, 2026. Ask the pharmacy what product it can actually obtain.

When were the prices and terms checked?

August 28, 2026. Manufacturer pricing, codes, program terms, generic status, and provider policies are scheduled for recurring checks below.

What can go stale on this page?

The prices, processing codes, program vendors, government-plan rules, provider terms, pharmacy inventory, and generic status can all change. The highest-risk items are the live-card processing block and the offer amounts, so those require monthly verification and a day-of-fill check by the reader.

Element	Refresh cadence	Verification method
$35, $45, $90, and $190 manufacturer amounts	Monthly	Live manufacturer savings page and current PDF
GoodRx $85/$205 manufacturer-listed route	Monthly	Manufacturer page and live GoodRx page
Retail and GoodRx processing information	Monthly and before publication	Compare live page with current download; save dated screenshots
PhilRx/Transition vendor wording and phone hours	Monthly	Manufacturer FAQ and PDF
Card eligibility and rebate terms	Quarterly	Current terms and FAQ
Generic approval/marketing status	Monthly	FDA Orange Book and pharmacy inventory check
FDA-approved Osphena label	Quarterly	DailyMed / Drugs@FDA
Medicare Part D out-of-pocket threshold	Each January	CMS and Medicare.gov
Part D formularies	Each plan year and when a reader reports a change	Exact plan formulary or plan phone call
MyMenopauseRx and Sesame terms, prices, and state availability	Monthly	Provider sites and terms
Third-party cash-price snapshots	Monthly	Live quantity-specific price pages

We do not change the “Last verified” date merely because a calendar month changed. It changes when the claims on the page are actually rechecked.

The short version

Commercial insurance: compare $90 for 90 through Osphena At Home with $45 for 30 at retail. No insurance or no coverage: compare $190 for 90 by mail with $85 for 30 or $205 for 90 through the listed GoodRx route. Medicare: compare Part D coverage before paying cash outside the benefit. Medicaid and TRICARE: the published manufacturer offers exclude you.

If you have commercial insurance, ask whether a 90-tablet prescription is clinically appropriate and whether the mail route can process it. The advertised annual difference from 30-tablet retail fills is $180.

If you are uninsured or Osphena is not covered, the lowest published manufacturer cash amount is $190 for 90 through Osphena At Home. Confirm it before the prescription is transferred.

If you have Medicare Part D, the commercial card is not your route. Compare the plan's covered price and exception process with the $190 cash transaction, remembering that cash outside Part D does not count toward the $2,100 threshold.

If you have Medicaid, TRICARE, or another government plan, do not assume Medicare's separate cash language applies. Call the plan and the program.

If the card fails, ask for the exact rejection message. Open the live savings page instead of handing over an old printout.

Your price is not the number in a headline. It is the number produced by the correct route, quantity, payer, and current processing information.

Still not sure which HRT program is right for you? Take our free matching quiz.

Use The HRT Index's Find My HRT Path tool

It matches your situation to the right provider — and flags when online care isn't the right starting point — before your first consult. Because the tool asks about health information, it is governed by our consumer health data privacy policy.

Sources

Manufacturer and program terms

Medical and regulatory

Medicare

Current price and access context

Educational information only. Not medical advice. This editorial research was not medically reviewed by a clinician. See our medical review policy.

Keep the savings-card question in context

Compare Osphena cash-price routes, review Osphena insurance rules, and check Medicare Part D coverage before deciding how to fill the prescription.

Keep reading: